Reply to “promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy”
Journal of Gastroenterology · 2024
DOI: 10.1007/s00535-024-02113-y ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Gastroenterology, 2024. Verfasst von Makoto Naganuma. Beteiligte Einrichtung: Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-…. Hauptthemen laut MEDLINE: Infliximab, Colitis, Ulcerative, Gastrointestinal Agents. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan. naganuma@hirakata.kmu.ac.jp.
ORCID-Profile: Makoto Naganuma
Zitieren
APA
Naganuma, M. (2024). Reply to “promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy”. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02113-y
Vancouver
Naganuma M. Reply to “promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy”. Journal of Gastroenterology. 2024. doi:10.1007/s00535-024-02113-y
BibTeX
@article{Naganuma2024,
author = {Naganuma, Makoto},
title = {Reply to “promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy”},
journal = {Journal of Gastroenterology},
year = {2024},
doi = {10.1007/s00535-024-02113-y}
}
EUVIMED